Novel pharmaceuticals for the management of retinal vein occlusion and linked disorders
M Driban, N Kedia, S Arora… - Expert Review of Clinical …, 2023 - Taylor & Francis
Introduction Retinal vein occlusion (RVO) is the second leading cause of blindness from
retinal vascular disease behind diabetic retinopathy. Anti-vascular endothelial growth factor …
retinal vascular disease behind diabetic retinopathy. Anti-vascular endothelial growth factor …
Systematic review of clinical practice guidelines for the diagnosis and management of retinal vein occlusion
J Galvez-Olortegui, R Bouchikh-El Jarroudi… - Eye, 2024 - nature.com
Background/objectives To assess the methodological quality of Clinical Practice Guidelines
(CPG) for the diagnosis and management of Retinal Vein Occlusion (RVO). Methods A …
(CPG) for the diagnosis and management of Retinal Vein Occlusion (RVO). Methods A …
[HTML][HTML] Efficacy and safety of Faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials
Purpose To evaluate the 24-week efficacy and safety of the dual angiopoietin-2 (Ang-2) and
vascular endothelial growth factor (VEGF)-A inhibitor faricimab versus aflibercept in patients …
vascular endothelial growth factor (VEGF)-A inhibitor faricimab versus aflibercept in patients …
A pivotal decade for bispecific antibodies?
M Surowka, C Klein - Mabs, 2024 - Taylor & Francis
Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms
of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of …
of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of …
Rates of ocular adverse events after intravitreal faricimab injections
B Momenaei, K Wang, AS Kazan, GJ Oh… - Ophthalmology …, 2024 - ophthalmologyretina.org
Abbreviations and Acronyms: AMD ¼ age-related macular degeneration; EZ ¼ ellipsoid
zone; NIR ¼ near-infrared reflectance; RIPL ¼ retinal ischemic perivascular lesion; RPD ¼ …
zone; NIR ¼ near-infrared reflectance; RIPL ¼ retinal ischemic perivascular lesion; RPD ¼ …
The protective effect of anti-VEGF-A/Ang-2 bispecific antibody on retinal vein occlusion model mice
A Kuriyama, S Nakamura, Y Inokuchi, H Abe… - European Journal of …, 2024 - Elsevier
Retinal vein occlusion (RVO) causes macular edema and retinal ischemia resulting in visual
field and vision loss. A bispecific antibody that blocks VEGF-A and angiopoietin-2 (Ang-2) …
field and vision loss. A bispecific antibody that blocks VEGF-A and angiopoietin-2 (Ang-2) …
Infographic: study design of the BALATON and COMINO phase 3 randomised trials of faricimab in patients with retinal vein occlusion
A Chang, A Kotecha, F Kermani, I Saffar - Eye, 2024 - nature.com
Fig. 1 This infographic summarises the design of two nearly identical phase 3 trials of
faricimab, a dual angiopoietin-2/vascular endothelial growth factor-A inhibitor, in patients …
faricimab, a dual angiopoietin-2/vascular endothelial growth factor-A inhibitor, in patients …
Faricimab maintains substance integrity and sterility after compounding and storage in two different polypropylene syringe types
S Waldstein, A Taschauer, A Sedivy, D Egger… - 2024 - researchsquare.com
Background: Compounding and storage of intravitreal anti-vascular endothelial growth
factor (anti-VEGF) agents in syringes is commonly performed in an off-label manner …
factor (anti-VEGF) agents in syringes is commonly performed in an off-label manner …
Current use of the faricimab in retinal diseases
B Saatcı, M Çıtırık - Ankyra Medical Journal, 2023 - journal-ankmj.com
Faricimab, a novel drug in the field of ophthalmology, has garnered attention because of its
promising applications in the treatment of various ocular conditions. This drug, with its dual …
promising applications in the treatment of various ocular conditions. This drug, with its dual …
[PDF][PDF] La FDA aprueba el uso del anticuerpo dual faricimab para tratar la oclusión venosa retiniana
MV Urrea - socesfar.es
La oclusión venosa retiniana (OVR) es una patología vascular de la retina que puede
producir diferentes grados en la pérdida de la visión (1). Es la segunda causa principal de …
producir diferentes grados en la pérdida de la visión (1). Es la segunda causa principal de …